← Back to Search

Anti-fibrotic agent

Pirfenidone for Sarcoidosis (PirFS Trial)

Phase 4
Waitlist Available
Led By Robert P Baughman, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up two years
Awards & highlights

PirFS Trial Summary

Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis

Eligible Conditions
  • Sarcoidosis

PirFS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~two years
This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time until clinical worsening (TCW)
Secondary outcome measures
Change in CPI
Change in forced vital capacity (FVC)

PirFS Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: PirfenidoneActive Control1 Intervention
Pirfenidone titrated to three 267 mg tablets three times a day
Group II: PlacebosPlacebo Group1 Intervention
Placebo titrated to three tablets three times a day

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
427 Previous Clinical Trials
634,302 Total Patients Enrolled
14 Trials studying Sarcoidosis
3,712 Patients Enrolled for Sarcoidosis
Royal Brompton & Harefield NHS Foundation TrustOTHER
224 Previous Clinical Trials
140,901 Total Patients Enrolled
2 Trials studying Sarcoidosis
250 Patients Enrolled for Sarcoidosis
Robert P Baughman, MDPrincipal InvestigatorUniversity of Cincinnati
10 Previous Clinical Trials
2,530 Total Patients Enrolled
9 Trials studying Sarcoidosis
2,515 Patients Enrolled for Sarcoidosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pirfenidone for Progressive Fibrotic Sarcoidosis
Robert P Baughman 2017. "Pirfenidone for Progressive Fibrotic Sarcoidosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03260556.
All > Stronger Than Sarcoidosis > Esbriet
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top